Journal article
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
Abstract
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed. This article aims to review the evidence …
Authors
N. K; Yip SM; Bauman G; Probst S; Emmenegger U; Kollmannsberger CK; Martineau P; Niazi T; Pouliot F; Rendon R
Journal
Current Oncology, Vol. 31, No. 3, pp. 1400–1415
Publisher
MDPI
DOI
10.3390/curroncol31030106
ISSN
1198-0052